In a strong show of support for the CF community, the U.S. Senate Appropriations Committee recently expressed the importance of innovative cystic fibrosis research in a spending bill, which is part of the federal budget under consideration right now in Congress.
Site Search
In 2011, Cystic Fibrosis Foundation advocates worked to advance cystic fibrosis research and help ensure access to treatment and care for people with the disease.
On March 8, more than 40 Cystic Fibrosis Foundation volunteers from across the nation came together on Capitol Hill to speak out on behalf of their friends and family members with cystic fibrosis.
The U.S. House of Representatives and the Senate have both incorporated the Expanding and Promoting Expertise in Review of Rare Treatments Act (EXPERRT Act), championed by the CF Foundation, as part of a legislative package to reauthorize the U.S. Food and Drug Administration's (FDA) system for evaluating new prescription drugs and devices.
Legislation Includes Measures to Increase Patient and Expert Participation in FDA Review of Rare Disease Drugs
The Cystic Fibrosis Foundation joins 15 patient and provider groups to oppose this bill, which would negatively impact patients' access to adequate and affordable health coverage and care.
A nonpartisan group of 29 patient, provider, and consumer groups praised the Senate Health, Education, Labor, and Pensions (HELP) Committee for crafting bipartisan legislation that will help stabilize the individual insurance markets.
As part of the Cystic Fibrosis Foundation's 11th annual March on the Hill, more than 100 advocates from 44 states met with nearly 300 elected officials or their staff to help ensure that everyone with cystic fibrosis has access to high-quality, specialized care and adequate, affordable health care.
Ten patient and provider groups, representing millions of Americans, issued the following statement in response to the release of the nonpartisan Congressional Budget Office's (CBO) scores of two pieces of health care reform legislation currently being considered by the U.S. Senate.